Goodfood Market Stock (OTC:GDDFF), Trade Ideas

Goodfood Market Corp is an online grocery company in Canada delivering fresh meal solutions and groceries that make it easy for members to enjoy delicious meals at home every day. The principal business activity is focused on developing and servicing the online meal kit and grocery add-on market. Goodfood members have access to products and exclusive pricing made possible by its direct-to-consumer fulfilment ecosystem that eliminates waste and retail overhead. It has a production facility and administrative offices in Montreal, with five additional facilities located in Quebec, Ontario, Alberta, and British Columbia. The Company is passionate about connecting its partner farms and suppliers to its customers' kitchens while eliminating food waste and costly retail overhead.

Goodfood Market Corp

Wedbush analyst Jay McCanless reiterates Century Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCS#NYSE">CCS</a>) with a Underperform and maintains $82 price target.

News

Price Target

Reiteration

Analyst Ratings

Wedbush Reiterates Underperform on Century Communities, Maintains $82 Price Target

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participants
PH15 was safe and well-tolerated with an adverse event profile similar to placebo
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com&amp;esheet=53955276&amp;newsitemid=20240425871950&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=a2d2fc9e17171d1883d5b05781b8544b">Vistagen</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.
The previously unreported randomized, double-blind, placebo-controlled, crossover Phase 2A pilot study of PH15 was designed to explore the efficacy, safety, and tolerability of intranasal administration of PH15 on psychomotor performance as measured by reaction time in sleep-deprived participants. Ten participants were randomly administered PH15 (multiple 1.6 µg doses, total dose of 9.6 µg), placebo (nasal spray and oral), or caffeine (single 400 mg oral dose administered 1 hour before the session) in sequential sleep deprivation study sessions spaced one week apart. During each sleep deprivation session, participants received blinded treatments before the start of each of four testing periods, at 6:00 p.m., 9:00 p.m., midnight, and 3:00 a.m. The participants' reaction times to both isochronous (regular interval) and stochastic (random interval) "flash" light stimuli were computer-measured during each testing period as participants responded to the luminous stimuli.
Statistically Significant Efficacy
During both isochronous and stochastic reaction time tests, administration of 1.6 µg PH15 nasal spray induced a significantly faster mean reaction time compared to placebo nasal spray across all time points (p&lt;0.001). PH15 also demonstrated a statistically significant improvement in reaction time compared to oral caffeine (p&lt;0.001) for both reaction time tests during the testing periods at midnight and 3:00 a.m. when subjects were most fatigued.
Well-tolerated Therapy
PH15 was well-tolerated with no serious adverse events reported. The adverse event profiles of PH15 and placebo were comparable, with brief nasal itching in one PH15-dosed participant and three placebo-dosed subjects. Participants on oral caffeine, however, experienced palpitations, euphoria, dry mouth, stomachache, and polyuria.
"In this Phase 2A pilot study, PH15 nasal spray demonstrated significant improvement in reaction time when compared to both oral caffeine and placebo in sleep-deprived participants. These pilot findings contribute to our confidence in PH15's potential as an innovative treatment for enhancing psychomotor performance and potentially cognitive impairment, particularly in addressing the challenges of mental fatigue," said Shawn Singh, Chief Executive Officer of Vistagen. "Numerous disorders, such as shift work disorder, sleep apnea, and narcolepsy, can lead to debilitating sleep deprivation and mental fatigue. Individuals affected by these disorders require improved treatment options with a differentiated safety profile, one without the potential for abuse liability or negative and treatment-limiting side effects and safety concerns. We anticipate exploring PH15's potential to emerge as a new and transformative solution for these underserved individuals."
This previously unreported Phase 2A pilot study of PH15 was sponsored by Pherin Pharmaceuticals (Pherin), now a wholly owned subsidiary of Vistagen, and conducted at the National Institute of Psychiatry, Sleep Disorders Clinic in Mexico City, Mexico in 2011. Vistagen gained access to the results of this study in connection with its acquisition of Pherin in February 2023. The late Jose Maria Calvo, MD, formerly Associate Professor, National Institute of Psychiatry in Mexico City, served as the Principal Investigator of the study.

Biotech

General

VTGN

Vistagen Announces Results From Phase 2A Pilot Study Of PH15 For Improvement Of Psychomotor Impairment Caused By Mental Fatigue

Jefferies analyst Brent Thill maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Hold and lowers the price target from $210 to $190.

Jefferies Maintains Hold on IBM, Lowers Price Target to $190

The partnership is set to transform infant care by providing virtual telehealth services to caregivers, increasing access to innovative medical-grade monitoring.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.owletcare.com%2F&amp;esheet=53955111&amp;newsitemid=20240425179815&amp;lan=en-US&amp;anchor=Owlet&amp;index=1&amp;md5=aaa85d451661a65fe8b2620275ee14c2">Owlet</a>, Inc. ("Owlet" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>), the pioneer of smart infant monitoring, announces a strategic partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.wheel.com%2F&amp;esheet=53955111&amp;newsitemid=20240425179815&amp;lan=en-US&amp;anchor=Wheel&amp;index=2&amp;md5=9c2d2f3959dbdf58c18dfbd08035f1df">Wheel</a>, an industry leader in providing virtual patient-centric care. Through this partnership, Wheel clinicians will provide caregivers of infants with timely prescriptions for <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fowletcare.com%2Fproducts%2Ffda-cleared-babysat&amp;esheet=53955111&amp;newsitemid=20240425179815&amp;lan=en-US&amp;anchor=BabySat%26%238482%3B&amp;index=3&amp;md5=f11b61eb5e9f154e24926c1da84dc0f6">BabySat&#x2122;</a>, Owlet's FDA-cleared infant pulse oximeter, ushering in a new era of digital healthcare solutions for families.
Annually, more than 450,000 babies transition home from the neonatal intensive care unit (NICU)1. Further, every year in the United States, Congenital Heart Disease (CHD) affects 40,000 babies2 and an estimated 58,000-80,000 children under five with respiratory syncytial virus (RSV) require hospitalization3. BabySat, featuring Owlet's signature wire-free sock design, empowers caregivers to more effectively monitor their baby's health and collaborate with healthcare providers to ensure optimal care.
"Home monitoring plays a pivotal role in safeguarding at-risk infants by improving access to health services," said Jim Fidacaro, Owlet Senior Vice President and General Manager of Healthcare. "Owlet, in partnership with Wheel, can now enable parents to obtain prescriptions for BabySat directly via Wheel's online portal and network of physicians. With a prescription, caregivers will then be able to order BabySat at little to no cost with insurance reimbursement."
The BabySat virtual telehealth services platform, managed and powered by Wheel, also integrates with durable medical equipment (DME) suppliers who accept and can bill for the product through many insurance providers, who may offer up to 100% reimbursement for BabySat. This new, streamlined process makes advanced monitoring even more accessible by significantly reducing the effort and time needed to secure BabySat and get reimbursed through insurance or HSA/FSA.
"We're thrilled to announce our strategic partnership with Owlet, a leader in smart infant monitoring. This collaboration marks a significant milestone in our mission to expand healthcare access and simplify care delivery for all Americans — especially for growing families," said Wheel CEO, Michelle Davey. "Wheel's virtual care platform helps streamline access to home monitoring, making Owlet's BabySat pulse oximeter more convenient for new parents than ever before."
Detailed information on BabySat and the telehealth services process are available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fowletcare.com%2Fproducts%2Ffda-cleared-babysat&amp;esheet=53955111&amp;newsitemid=20240425179815&amp;lan=en-US&amp;anchor=www.owletcare.com&amp;index=4&amp;md5=d042d2294b4b17e2db46546e59022bd8">www.owletcare.com</a>. These partnerships reflect Owlet's commitment to providing accessible, high-quality care for infants and their families.

OWLT

Owlet Forges Partnership With Wheel To Launch Virtual TeleHealth Services Platform

25 April 2024, 14:30 CET
ArcelorMittal (‘the Company') today announces the publication of its first quarter 2024 sell-side analyst consensus figures.
The consensus figures are based on analysts' estimates recorded on an external web-based tool provided and managed by an independent company, Visible Alpha.
To arrive at the consensus figures below, Visible Alpha has aggregated the expectations of sell-side analysts who, to the best of our knowledge, cover ArcelorMittal on a continuous basis. Sell-side analysts follow ArcelorMittal on their own initiative and ArcelorMittal is not responsible for their views. ArcelorMittal is neither involved in the collection of the information nor in the compilation of the estimates.
1Q'24 consensus estimates&#x2A;:
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;1Q'24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>EBITDA ($m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $1,814&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Net income ($m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $733&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Earnings per share ($)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; $0.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</li>
</ul>
&#x2A; Number of sell-side analyst participation is 6 brokers (i.e. those who have updated estimates in Visible Alphas and reflected the Groups new EBITDA definition and reportable segmentation).
2023 Factbook published
The Company has filed its 2023 Factbook reflecting the presentation of reportable segments and EBITDA for the following periods where applicable: FY 2021, FY 2022 and FY 2023 and quarters of 2022 and 2023. Company's published 2023 Factbook can be viewed <a href="https://www.globenewswire.com/Tracker?data=G5bqcRZL-qhhDaFstc95EsnvYqgYYFfTRvazC4vS_yvFOAxAPt3K4BgaOoFQULuQhRelmfN18wBkPkLuy3V8Occ88bluUCrR3LAMqk4ulhpnGSRxJF0zr0pb3E3ztBnXxWf0cHDnrPo2JQwHFW2gdMX3wTKfM5ObKeJzHyWO85Q=">here.</a>

Guidance

ArcelorMittal S.A.: ArcelorMittal Announces Q1 2024 Sell-Side Analyst Consensus Figures Of EPS $0.91; Net Income $733M, EBITDA $1.814B

WIIM

OMQS

OMNIQ shares are trading higher after the company announced a follow-on order for its AI-based machine vision solution for a Homeland Security project.

International Paper Company shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Also, the company announced that its incurred a $52 million impairment charge in Q1 due to January freeze and the Ixtac, Mexico fire

Contracts

OMNIQ Receives Follow On Order For Its AI-Based Machine Vision Solution For A Homeland Security Project; Terms Not Disclosed

Piper Sandler analyst James Fish maintains HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) with a Neutral and raises the price target from $25 to $35.

Piper Sandler Maintains Neutral on HashiCorp, Raises Price Target to $35

HarborOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.11 by 54.55 percent. This is a 6.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $30.58 million which beat the analyst consensus estimate of $29.25 million by 4.55 percent. This is a 11.09 percent decrease over sales of $34.40 million the same period last year.

Earnings

HONE

HarborOne Bancorp Q1 EPS $0.17 Beats $0.11 Estimate, Sales $30.58M Beat $29.25M Estimate

Buybacks

HAFC

Hanmi Financial Announces New Share Repurchase Authorization Of Up To 1.5M Shares

SPDR Dow Jones Industrial Average ETF Trust

QQQM

Major indexes are lower following softer-than-expected US GDP growth.

Ladder Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LADR#NYSE">LADR</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.29 by 13.79 percent.

Earnings Beats

LADR

Ladder Cap Q1 2024 Adj EPS $0.33 Beats $0.29 Estimate

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares fell on Wednesday following the airplane manufacturers&#8217; quarterly results, and a bullish analyst said the recovery route from the current predicament could be a long-drawn one.
Twin Focus Areas: There are two things that are key to the Boeing story now &#8211; a potential buyout of supplier Spirit AeroSystems Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPR#NYSE">SPR</a>) and roping in a new CEO, said Langenberg &amp; Co. founder Brian Langenberg said in an interview with CNBC.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Boeing&#39;s clean up will be a multi-year affair, says Brian Langenberg. he has a Buy on the stock with a $275 PT but a lot hinges on the new CEO.<a href="https://twitter.com/WillKoulouris?ref_src=twsrc%5Etfw">@willkoulouris</a> <a href="https://twitter.com/search?q=%24BA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BA</a> <a href="https://t.co/xhMzua0QvU">pic.twitter.com/xhMzua0QvU</a>
&mdash; CNBC&#39;s Street Signs (@StreetSignsCNBC) <a href="https://twitter.com/StreetSignsCNBC/status/1783345244773462106?ref_src=twsrc%5Etfw">April 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
With on-and-off rumors regarding a potential Spirit AeroSystems buy since last year, it has become a &#8220;have-to-think&#8221; by the legacy existing management, the analyst said. 
Langenberg said he sees a couple of silver linings. If Boeing opts to buy Spirit AeroSystems now, it wouldn&#8217;t be buying at peak profitability and therefore, there is upside from that, he said. Also, the analyst said the company may not lose out on Spirit AeroSystems&#8217; Airbus business. &#8220;Aviation is a industry where there is a lot of collaboration, even among rivals, and they wouldn&#8217;t necessarily lose the Airbus business, because Airbus maybe doesn&#8217;t want to, well, bend metals,&#8221; he said. 
Long-term Fix: Langenberg said <a href="https://www.benzinga.com/markets/equities/24/03/37929869/quest-for-leadership-boeing-reportedly-eyes-outsider-as-ceo-to-tackle-crisis">the responsibility of fixing Boeing on a longer-term basis lies with the CEO, </a>who will have to make the most important decision of picking the right airplane programs, both on the commercial and defense side.
&#8220;But then the other part is, it has to be someone who is committed and focused to getting Boeing&nbsp;into being an engineering-driven organization again, and that means less reported profits&nbsp;near term, but save the company and rebuild its health long term,&#8221; he said.
&#8220;So it&#8217;s the near term stabilizing the production, and the long term fixing the company.&#8221;
See Also: <a href="https://www.benzinga.com/money/best-industrials-stocks">Best Industrial Stocks Right Now</a>
Value Trap? Langenberg also weighed in on whether it is prudent to buy the stock and play the long game until things improve or whether the stock has become a value trap. The analyst said he has a Buy rating on Boeing, although he said he missed a downgrade opportunity when the stock was at $250.
&#8220;I didn&#8217;t expect things to start falling apart in midair,&#8221; the analyst said. 
&#8220;So, you know, anywhere at this price, $164, $175, anywhere around here, okay,&#8221; he said, adding &#8220;if they get it right, it&#8217;s an incredible opportunity.&#8221;
If Boeing doesn&#8217;t get it right, down the road, it would prove to be a value trap, he said.
&#8220;Anybody who&#8217;s recommending the stock, including myself, isn&#8217;t making an implicit judgment that this can&#8217;t be fixed. And I think it can be fixed, but that comes down to, you know, who&#8217;s the next leader,&#8221; Langenberg said.
In premarket trading on Thursday, the stock fell 0.44% to $163.60, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data.</a>
Read Next:<a href="https://www.benzinga.com/news/24/04/38418530/boeing-isnt-junk-status-yet-moodys-outlook-on-aircraft-maker-goes-negative"> Boeing Isn&#8217;t Junk Status — Yet: Moody&#8217;s Outlook On Aircraft Maker Goes Negative</a>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Image Via Shutterstock

Analyst Color

Equities

Media

Trading Ideas

Bullish Boeing Analyst Says 'Didn't Expect Things To Start Falling Apart In Midair:' 'If They Get It Right, It's An Incredible Opportunity'

Piper Sandler analyst Harsh Kumar reiterates Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Overweight and raises the price target from $130 to $150.

Piper Sandler Reiterates Overweight on Impinj, Raises Price Target to $150

Mangoceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgrx#NASDAQ">MGRX</a>) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair
Mangoceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>) ("<a href="https://www.globenewswire.com/Tracker?data=iyzEps3bM8NuvvmXlQD9-SSm3-YNnizQkE8OjYH9fO_qQ376gKQyVUmmLeGyiC3ceZT4I_Og4PnFos1g2jluhw==">MangoRx</a>" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the "Patent Portfolio") from Intramont Technologies, Inc. ("Intramont"), pursuant to a Patent Purchase Agreement ("PPA").

Penny Stocks

MGRX

MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares

Theriva&#x2122; Biologics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of the science and its relevance, VIRAGE - the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) - has been accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, from May 31-June 4. &nbsp;
ASCO Presentation Details
<ul>
<li>Title: VIRAGE: A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer</li>
<li>Presenter: Dr. Rocío García-Carbonero</li>
<li>Session Title: Poster Session – Gastrointestinal Cancer: Gastroesophageal, Pancreatic, and Hepatobiliary</li>
<li>Poster Session Date and Time: 01 June 2024, 1:30 PM-4:30 PM US CDT
<ul>
<li>Abstract Number: TPS4210</li>
</ul>
</li>
</ul>

TOVX

Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

Jefferies analyst George Notter downgrades Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) from Buy to Hold and lowers the price target from $48 to $30.

Downgrades

CALX

Jefferies Downgrades Calix to Hold, Lowers Price Target to $30

Piper Sandler analyst Thomas Champion reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and lowers the price target from $600 to $545.

Piper Sandler Reiterates Overweight on Meta Platforms, Lowers Price Target to $545

Kearny Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. This is a 29.41 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $34.319 million which missed the analyst consensus estimate of $34.380 million by 0.18 percent. This is a 19.00 percent decrease over sales of $42.371 million the same period last year.